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Abstract 
A cDNA coding for a human type VIII adenylyl cyclase has been isolated from human newborn brain-stem tissue. This cDNA is 6,005 bp long 
and encodes for a protein of 1251 amino acids, exhibiting the two sets of six transmembrane spanning regions and the hydrophobicity profile typical 
of other mammalian adenylyl cyclases. Comparison with the rat form shows that they share 97% identity in amino acids. Type VIII adenylyl cyclase 
is unique in that it has both a long carboxy terminal and a long amino terminal tail. This is the first report on a complete cDNA clone coding for 
a human adenylyl cyclase. The distribution and regulation of this particular adenylyl cyclase suggest hat it may be involved in learning, in memory 
and in drug dependence. 
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1. Introduction 
Cyclic AMP is a second messenger for a variety of 
hormones and neurotransmittors acting via trimeric G 
protein-coupled receptors. It is synthesized by adenylyl 
cyclases (AC) which were initially classified as either 
calmodulin-sensitive or -insensitive enzymes. The ex- 
treme diversity of the regulation of the adenylyl cyclase 
activity was thought to be related to the combinatorial 
association of a large number of receptors with the 
isotypes of a, /3 and y subunits of the G proteins. In the 
last few years, it has become clear that the multiplicity 
of adenylyl cyclase isoforms contributes to the diversity 
and specificity of this signal transduction system. Indeed, 
since the purification and cloning of the first AC from 
bovine brain [l], full-length cDNAs have been reported 
for seven different types of AC in different tissues and 
different species [2]. Each of these different cyclases dis- 
plays specific patterns of sensitivity to the a, p and y 
subunits of the G proteins, and to CalciumKalmodulin 
(Ca”lCam). Until recently, no full-length cDNA for AC 
had been isolated from human libraries. Only partial 
cDNA sequences have been obtained for the human 
forms of AC: in our laboratory, we have isolated, from 
human brain, partial cDNAs encoding two types of AC, 
now refered as type II and type VIII, respectively [3,4]; 
a partial cDNA for type I has been isolated from human 
fetal brain [5]. In the human genome, all the known 
adenylyl cyclases are localized on different chromosomes 
[4-61 and thus their expression might be independently 
regulated. As part of our effort to study the role of the 
different adenylyl cyclases in human physiology and dis- 
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2. Materials and methods 
2. I. cDNA cloning and screening procedure 
Total RNA was prepared from newborn brain-stem tissue according 
to Chomczynski and Sacchi [7]. Poly(A)’ RNA was isolated by 
oligo(dT) cellulose (Pharmacia) chromatography according to Aviv 
and Leder [8]. The cDNA library was produced by using the pTZ18R 
vector (Gibco-BRL) as previouly described 191. Briefly, the pTZ18R 
plasmid was linearized using PstI, and (dC)-tailed using terminal trans- 
ferase. Tailed molecules were digested with BamHI and the small frag- 
ment, generated by BarnHI cleavage, was removed by spin dialysis 
through Sephacryl S-400 (Pharmacia). cDNA was produced from 1 pg 
of poly(A)’ RNA using synthetic oligo(dT) as primer. Residual RNA 
was removed by alkaline hydrolysis. The cDNA was (dG)-tailed and 
then selected in size above 3 kb in a low-melting point agarose gel. 
Finally the 5’ terminal end of the cDNA was converted into BamHI 
‘sticky-end’ by addition of a BamHI adaptor. Subsequently, the single- 
stranded cDNA was joined to the vector by ligation to produce circular 
molecules, repair of the single-stranded region was accomplished by 
using the (dC) tail of the vector as a primer and T4 DNA polymerase 
(Gibco-BRL). 
Approximately 2.106 clones were screened using, as probes, radioac- 
tive oligonucleotides complementary to the previously described se- 
quence [3]. The probes were radiolabelled using [a-32P]dCTP and termi- 
nal deoxynucleotidyltransferase ccording to the standard method [IO]. 
Prehybridization and hybridization were performed in 6 x SSC, 
3 x Denhardt’s and 0.5% SDS for 2 h at 42°C and filters were washed 
3 times with 6 x SSC, 0.1% SDS at 50°C for 20 min. Two positive 
overlapping clones were obtained, only the longer one (6,005 bp) was 
completely sequenced. 
2.2. DNA sequencing and sequence analysis 
Fragments of the cDNA have been subcloned in the pTZl8R vector. 
Both strands were sequenced by the dideoxynucleotide method, from 
a set of subclones and using different synthetic oligonucleotides [l11. A 
computer program based on the method described by Kanehisa [12], 
and using the matrix of Dayhoff [13] was used to define regions of 
homologies between the amino acid sequence of human type VIII AC 
and the sequences of all the known mammalian AC species. Alignment 
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was performed using the Clustal program [14] Sequence analysis was 
performed using the programs of the genetic computer Group Package 
(UWGCG). A search for homologous sequences was performed using 
the SwissPro and Gene EMBL databases. The sequence has been sub- 
mitted to EMBL databank under the Accession Number 235309. 
3. Results and discussion 
A 2,183 bp cDNA fragment encoding the C-terminal 
683 amino acid sequence of the human type VIII ade- 
nylyl cyclase has previously been identified from a 
human brain (frontal lobe) cDNA library, and was ini- 
tially referred to as type V [3]. Using oligonucleotides 
complementary to the 5’ end of this sequence and a 
modified RACE protocol [ 151, several overlapping 
clones were obtained which allowed us to determine an 
incomplete 2,988 bp cDNA sequence. Different oligonu- 
cleotides from this sequence have been used to screen a 
new cDNA library from human newborn brain-stem 
leading to the identification of one clone of 6,005 bp. 
Partial sequencing and restriction analysis confirmed the 
presence of the previously identified 3’ end sequence in 
this clone. The first putative initiation codon, in a con- 
text of a reasonable Kozak consensus sequence [16], is 
preceded by a 2,094 bp of non-coding sequence including 
stop codons in all three phases. In particular we have 
identified a stop codon (UAG) 60 bp upstream of this 
AUG in the same frame. This region is highly GC-rich. 
The open reading frame encodes a protein of 1,251 
amino acids (Fig. 1) with a deduced molecular weight of 
140 kDa. The hydrophobicity profile of the type VIII 
adenylyl cyclase is similar to that of the other membrane 
bound adenylyl cyclases with the 12 predicted trans- 
membrane spanning regions [17]. Three putative N- 
linked glycosylation sites exist between membrane span- 
ning regions 9 and 10 at amino acid positions 817 and 
821, and between membrane spanning regions 11 and 12 
at amino acid position 887, as found for most of the 
adenylyl cyclases. A potential protein kinase A phospho- 
rylation site can also be detected in the second portion 
of the first cytoplasmic loop, as also described for ade- 
nylyl cyclases types II, 111,V and VI [17-211. 
Recently, Cali et al. [22] published the sequence of a 
type VIII AC from rat brain; a 88% identity in nucleotide 
sequence and 97% identity in amino acid sequence exists 
between these two forms (Fig. 1). The major difference 
between these two cyclases resides in the absence of three 
serine residues in the NH, terminal part of the rat mole- 
cule. It is noteworthy that the carboxy-terminal cytoplas- 
mic domains of human and rat type VIII have more than 
90% identity in amino acid sequence. The same region 
of human and bovine type I is less conserved across 
species [5]. No significant homology was found between 
type I and type VIII in this part of the molecule. 
Type VIII adenylyl cyclase is unique among the 
cyclases in having both a long NH, terminal tail as in 
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Fig. I. Comparison of deduced amino acid sequences of human and rat 
type VIII adenylyl cyclases. Alignment of human and rat type VIII 
adenylyl cyclases amino acid sequences. Residues identical in both 
sequences are indicated with (-). (*) Represents the Serine gaps in the 
rat sequence. (a) Indicates the positions of the putative N-glycosylation 
sites. Predicted trans membrane regions are indicated as underligned 
sequences. 
type V and VI (type VIII: 182 aa; type V: 164 aa: type 
VI: 150-160 aa; type I: 63 aa; type II: 44 aa; type III: 77 
aa; and type IV: 28 aa), and a long COOH terminal tail 
as in type I (type VIII: 80 aa; type I: 76 aa; type II: 13 
aa; type III: 23 aa; type IV: 14 aa; type V: 5 aa; and type 
VI: 4 aa). These N- and C-terminal regions may support 
specific functions for the different cyclases. By express- 
ing rat type VIII in 293 cells, Cali et al. 1221 have demon- 
strated that this adenylyl cyclase is sensitive to Calcium/ 
Calmodulin, a property that is shared with type I and 
type III AC. Using point mutagenesis, it has been shown 
that amino acids within the sequence 495-522 of type I 
adenylyl cyclase contribute to the CaM binding domain, 
but no similar sequence is found in human type VIII. 
Sequences that are involved in calmodulin binding usu- 
ally contain a mixture of cationic and hydrophobic 
amino acids that can form an amphiphilic alpha helix 
[23], such structures may exist in different regions of the 
type VIII molecule. 
Using computational matching programs, the amino 
acid sequences of all the known 16 mammalian adenylyl 
cyclases have been aligned. Sequence comparison had 
allowed one to define 8 different types; within each type, 
adenylyl cyclases from different species shared 88-97% 
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Fig. 2. Comparison of the amino acid sequences of the different ade- 
nylyl cyclases with that of human type VIII adenylyl cyclase. The 
relative positions of the different domains has been determined from 
the alignment of all the known AC and the positions of the sequences 
which are predicted to form membrane associated helices. A computer 
program based on the method described by Kanehisa [12], and using 
the matrix of Dayhoff [13] was used to define regions of homologies 
between the amino acid sequence of human type VIII AC and the 
sequences of all the known mammalian AC. Alignment was performed 
using the Clustal program [14]. Since within one AC type the identity 
is at least of 90%, one member of each type is reported for the compar- 
ison (Bovine type I [l], Rat type II [19], Rat type III [18], Rat type IV 
[35], Canine type V [20] and rat type VI 1211. The number reported 
above each domain represent the degree of identity of this domain with 
the corresponding domain of human type VIII AC. Data about type 
VII are too sketchy to be included in the present scheme. 
identity in amino acids, whereas only 30 to 35% identity 
is detected between cyclases from different types; these 
differences reside mostly in the trans-membrane spans. 
Alignment of the amino acid sequences and comparison 
of the percentage of amino acid identity clearly reveals 
the presence of 5 major domains, as already proposed 
from the hydrophobicity profiles: the NH, terminus (N), 
the two trans-membrane regions (M, and M2) and the 
two cytoplasmic atalytic loops (C, and C,). Fig. 2 shows 
the comparison between these different major domains 
of the different types of adenylyl cyclases with the corre- 
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sponding domains of the human type VIII. As men- 
tioned above, the carboxy terminal part of the C2 domain 
(C,b) is only present in type I and type VIII adenylyl 
cyclases, and to a lesser extent in type III. Type I AC has 
been described as being neural specific [24], and type 
VIII AC appears to be essentially expressed in the brain 
[22,25]. There is no homology between type I and type 
VIII AC in the carboxy terminal part of the molecule. In 
the NH2 terminal domain (N), a low level of identity 
(31%) is found between type VIII and type V, and no 
homology exists with type VI; this region is highly type 
specific. The amino terminal part of the C2 domain 
(C2a) is the most conserved part of the enzyme between 
the different types (more than 50% amino acid identity). 
The second most conserved region is the cytoplasmic C, 
domain; a high degree of homology exists between C, 
and C2 in all the types of adenylyl cyclases and both 
domains are required for the catalytic activity [26,27]. In 
this region, type VIII has a lower homology with type II 
and type IV than with the other adenylyl cyclases. The 
trans-membrane domains M, and M, appear to be type 
specific, since they differ from one cyclase to another 
(approximately 20% identity); however some positions 
are conserved in the different types (Fig. 3): Tyr at posi- 
tion 174, and Leu, Pro at position 177-178 of human 
type VIII both at the end of the 4th putative trans- 
membrane span, Gly at the end of the 6th span, and Lys 
at the end of the 11 th span; all these conserved positions 
are on the cytoplasmic side of the molecule, and thus 
might be involved either in the catalytic site or in the 
interaction with the Ga subunit. Moreover, between the 
ninth and the tenth span, all the cyclases have one or two 
putative N-glycosylation site(s). Fig. 3 shows the con- 
served positions between the different adenylyl cyclases. 
It is noteworthy that in all the cases, a tyrosine is present 
9 amino acids before the Ml domain, another tyrosine 
is also present 3 amino acids before the M2 domain. 
Another striking observation made from sequence com- 
Cl 
Fig. 3. Conserved regions of the adenylyl cyclases. Alignment of the seven types of adenylyl cyclases. Alignments have been performed as decribed 
under legend to Fig. 2. 1,2,3,4,5,6, and 8 are the numbers of the different types of adenylyl cyclases. Residues identical in all the AC are indicated 
by: (-) Numbers in parentheses correspond to the number of amino acids in the less conserved regions. Most conserved modifications appeared as 
(*). The nature of these amino acids are not indicated. 
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parison was the fact that conserved amino acids or 
stretches of amino acids are separated by spaces of con- 
served length (Fig. 3). All the conserved positions are 
likely to confer to the adenylyl cyclases both their struc- 
ture and their catalytic activity. 
By Northern blot analysis we found two types of 
mRNA of 10.5 and 5.5 kb in human brain [3]. In rat 
brain, using the type VIII oligonucleotide specific probe, 
described by Cali et al. [22] for in situ hybridization, we 
found the two major forms of appoximately 4.4 and 5.5 
kb as described [22], but also a faint band at 7.5 kb. In 
human brain, we did not find the 4.4 kb form . All those 
results suggest he presence of several forms of AC type 
VIII . Indeed, only one gene for type VIII AC has been 
detected on human chromosomes (8q24); It is thus very 
likely that the different forms are produced either via an 
alternative splicing or use of alternative promotors or of 
different polyadenylation signals. Similar hypotheses 
have been proposed to account for the different forms of 
type V AC in canine heart mRNAs [20]. In addition, by 
screening a /ZGt 10 cDNA library from human testis, we 
isolated a partial 2 kb cDNA sequence which is identical 
to the 3’ end of the human brain type VIII, but contains 
a 90 bp deletion localized in the second transmembrane 
domain leading to the loss of the region between the 
membrane spans 9 and 10, and of two potential N-glyco- 
sylation sites (not shown). The complete cDNA sequence 
of this AC has not yet been obtained and we do not know 
if other deletions are present in this AC form in testis. 
Because of the structural similarity of type I and type 
VIII AC, it was of interest to compare their relative 
distribution in various regions of the brain. By in situ 
hybridization, type VIII adenylyl cyclase has been found 
to be expressed in unique structures of the brain, partic- 
ularly in the pyramidal and granular cells of the hip- 
pocampus, but also in several nuclei of the brain stem 
such as the pontine nuclei, the facial nucleus, lateral 
reticular nucleus and the locus coeruleus [22, 251. This 
distribution is compatible with the distribution of the 
Ca’+/Cam sensitive adenylyl cyclase activity and the dis- 
tribution of the Cam mRNA [25]. Both type I and type 
VIII are expressed in several regions of the brain which 
are associated with learning and memory, but with dis- 
tinct relative levels of expression [22,25,28,29]. Cali et al. 
thus proposed that both type VIII and type I are required 
for the development of long-term potentiation in the 
hippocampus [22]. The important role of the AC type 
VIII in brain function was strongly supported by the 
observations made on its regulation by opioids. Indeed 
acute opioid administration decreases the AC activity 
both in cell culture and in brain from treated animals, by 
acting on G-protein coupled receptors [30-333. It has 
been proposed that during chronic exposure to mor- 
phine, neurons could dramatically increase their AC ac- 
tivity to overcome the constant inhibition of the enzyme. 
In a recent paper, we provide direct experimental evi- 
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dence that chronic morphine treatment in mice induces 
a selective increase in type VIII AC mRNA transcripts 
in the locus coeruleus, the amygdala and the thalamus, 
all structures which have been shown to be critically 
involved in morphine abstinence [34]. 
At present, eight different types of AC have been re- 
ported [2]. For seven of them, the chromosomal localiza- 
tion has been determined [4-61; all of them are localized 
on different human chromosomes and might be, at least 
in part, independently regulated at the gene level. The 
gene for type VIII adenylyl cyclase is located on chromo- 
some 8 at the q24 band; two important genes are located 
in the proximity of this gene: the c-myc oncogene and the 
thyroglobulin gene. In Burkitt’s lymphoma, c-myc is 
translocated on a different chromosome near the immu- 
noglobulin gene cluster, thus modifying its expression. It 
would therefore be interesting to study the expression of 
type VIII AC in Burkitt’s lymphoma. This should now 
be possible since the entire sequence of the cDNA is 
available. To date, no pathology has been directly as- 
signed to a genetic change in the expression of any type 
of adenylyl cyclase. Most of the known alterations in the 
production of cyclic AMP originate from other compo- 
nents of the cyclase system, hormonal recptors or G 
proteins. Again, the availability of entire sequence of 
human adenylyl cyclase should help the search for alter- 
ations in the structure of AC associated with human 
diseases. 
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